Topline data were announced from a phase 3b trial evaluating investigational semaglutide 7.2mg in adults with obesity.
Zacks.com on MSN5d
NVO Stock Down as Medicare Selects Semaglutide Drugs for Price CutsNovo Nordisk’s NVO shares lost 5.3% on Friday after Medicare issued a press release selecting the company’s popular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback